XORTX Therapeutics Inc.

XRTX • Biotechnology

$2.31

▲ +0.16 (+7.44%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$3.74M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.02Healthy liquidity · 1.61Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 19, 2026, 12:24 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.31

Change7.44%

Shares Out1.62M

Market Cap$3.74M

Enterprise Value$2.74M

52W Range1.73 - 7.05

Beta0.08

P/E-1.01

P/B0.68

P/FCF-0.72

EV/EBITDA-0.73

EV/FCF-0.53

Price$2.31

Change7.44%

Shares Out1.62M

Market Cap$3.74M

Enterprise Value$2.74M

52W Range1.73 - 7.05

Beta0.08

P/E-1.01

P/B0.68

P/FCF-0.72

EV/EBITDA-0.73

EV/FCF-0.53

Earnings Yield-98.91%

FCF Yield-138.45%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.02

Current Ratio1.61

Quick Ratio1.61

Volume7.59K

Avg Volume22.80K

EPS Surprise0.39

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

73/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Manageable debt level · 0.02Healthy liquidity · 1.61Weak profitability

Analyst view

No analyst data available now.

Company Overview

IPO: 9/23/2021

Industry: Biotechnology

P/B i: 0.68

Debt / Equity i: 0.02

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.02

Current Ratio: 1.61

Quick Ratio: 1.61

Status: Good

🧾

No insider activity

No recent insider transactions available.

About the Company

XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.

Source - link

Peers

ATXI DRMA ELAB GTBP LEXX MLEC NCEL NKGN VRAX WINT

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

XORTX Announces Termination and Postponement of Investor Relations Program

CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “IR Agreement”). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable in advance. The fee was fully earned upon receipt and non-refundable. Under the mutual agreement of the parties, the arrangement has been rescinded, all services contemplated under the agreement have been discontinued and the funds previously paid to IR Agency LLC in connection with the agreement were returned to the Company on August 14, 2026. The original arrangement was disclosed in connection with the Company's US$5 million public offering completed on May 19, 2026. A portion of the offering proceeds, in an amount equal to US$2.5 million, had been allocated to IR Agency LLC for marketing and advertising services.

GlobeNewsWire

XORTX Announces Director Resignation

CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests. Dr. Allen Davidoff, co-CEO of XORTX, stated, “XORTX management and the board of directors extends our heartfelt appreciation for Mr.

GlobeNewsWire

XORTX Appoints New Director

CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the appointment of Depesh Narotam to the board of directors as an independent director. Depesh Narotam has been in the financial services industry for over 20 years.

GlobeNewsWire

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs. The Company's current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead program for gout.

GlobeNewsWire

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-02-26	-0.83548	-0.45	0.38548
2025-11-14	-0.1671	-0.13	0.0371
2025-08-14	-0.25	-0.19	0.06
2025-05-19	-0.27	-0.19	0.08
2025-05-15	-0.29	-0.19	0.1
2024-11-14	-0.38313	-0.2	0.18313
2024-08-14	-0.50101	0.06	0.56101
2024-05-15	-0.4484	-1.24	-0.7916
2024-04-02	-0.67603	-0.48	0.19603
2023-11-14	-2.04063	-6.03	-3.98937
2023-08-14	-1.55715	-0.81	0.74715
2023-05-15	-1.31018	-0.99	0.32018